# Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma

> **NCT00124657** · PHASE1,PHASE2 · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 62 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** Erlotinib hydrochloride

## Key facts

- **NCT ID:** NCT00124657
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2012-07
- **Final completion:** 2014-09
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2015-12-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00124657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00124657, "Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00124657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*